Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 10. М.; 2021. 222 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdf.https://webmed.irkutsk.ru/doc/pdf/algosd.pdf
Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 10. М.; 2021. 222 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdf.https://webmed.irkutsk.ru/doc/pdf/algosd.pdf
DeFronzo R.A., Inzucchi S., Abdul-Ghani M., Nissen S.E. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133–143. https://doi.org/10.1177/1479164118825376..
DOI: 10.1177/1479164118825376
Rawshani A., Rawshani A., Franzén S., Eliasson B., Svensson A.M., Miftaraj M. et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017;376(15):1407–1418. https://doiorg/10.1056/NEJMoa1608664..
DOI: 10.1056/NEJMoa1608664https://doiorg/10.1056/NEJMoa1608664
Салухов В.В., Ромашевский Б.В. Современные аспекты превентивной терапии сахарного диабета 2-го типа. Медицинский совет. 2019;(4):6–13. https://doi.org/10.21518/2079-701X-2019-4-6-13..
DOI: 10.21518/2079-701X-2019-4-6-13
Low Wang C.C., Hess C.N., Hiatt W.R., Goldfine A.B. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133(24):2459–502. https://doi.org/10.1161/CIRCULATIONAHA.116.022194..
DOI: 10.1161/CIRCULATIONAHA.116.022194
Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494–510. https://doi.org/10.14341/DM8216..
DOI: 10.14341/DM8216
Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925..
DOI: 10.1056/NEJMoa1611925
Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. https://doi.org/10.1056/NEJMoa1603827..
DOI: 10.1056/NEJMoa1603827
Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141..
DOI: 10.1056/NEJMoa1607141
Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3..
DOI: 10.1016/S0140-6736(19)31149-3
Chao L., Marcus-Samuels B., Mason M.M., Moitra J., Vinson C., Arioglu E. et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000;106(10):1221–1228. https://doi.org/10.1172/JCI11245..
DOI: 10.1172/JCI11245
Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. https://doi.org/10.1056/NEJMoa072761..
DOI: 10.1056/NEJMoa072761
Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. https://doi.org/10.1056/NEJMoa072761..
DOI: 10.1056/NEJMoa072761
Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586. https://doi.org/10.1001/jama.294.20.joc50147..
DOI: 10.1001/jama.294.20.joc50147
Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. https://doi.org/10.1016/S0140-6736(05)67528-9..
DOI: 10.1016/S0140-6736(05)67528-9
Аметов А.С., Сокарева Е.В. Пиоглитазон в лечении сахарного диабета 2-го типа. РМЖ. 2010;18(23):1423–1428. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Pioglitazon_v_lechenii_saharnogo_diabeta_2go_tipa.https://www.rmj.ru/articles/endokrinologiya/Pioglitazon_v_lechenii_saharnogo_diabeta_2go_tipa
Аметов А.С., Сокарева Е.В. Пиоглитазон в лечении сахарного диабета 2-го типа. РМЖ. 2010;18(23):1423–1428. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Pioglitazon_v_lechenii_saharnogo_diabeta_2go_tipa.https://www.rmj.ru/articles/endokrinologiya/Pioglitazon_v_lechenii_saharnogo_diabeta_2go_tipa
Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Кадин Д.В. Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2 типа: обзор основных стратегий и клинических исследований. Сахарный диабет. 2018;21(3):193–205. https://doi.org/10.14341/DM9570..
DOI: 10.14341/DM9570
Пешева Е.Д., Фадеев В.В. Пиоглитазон – забытый сахароснижающий препарат с доказанными кардиопротективными и нефропротективными свойствами. Consilium Medicum. 2021;23(4):366–371. https://doi.org/10.26442/20751753.2021.4.200892..
DOI: 10.26442/20751753.2021.4.200892
Nesti L., Tricò D., Mengozzi A., Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109. https://doi.org/10.1186/s12933-021-01294-7..
DOI: 10.1186/s12933-021-01294-7
Schernthaner G., Currie C.J., Schernthaner G.H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(2 Suppl.):S155–161. https://doi.org/10.2337/dcS13-2031..
DOI: 10.2337/dcS13-2031
Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C. et al. LongTerm Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305–315. https://doi.org/10.7326/M15-1774..
DOI: 10.7326/M15-1774
Deeg M.A., Buse J.B., Goldberg R.B., Kendall D.M., Zagar A.J., Jacober S.J. et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458–2464. https://doi.org/10.2337/dc06-1903..
DOI: 10.2337/dc06-1903
Hurren K.M., Dunham M.W. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? Expert Opin Pharmacother. 2021;22(2):131–133. https://doi.org/10.1080/14656566.2020.1853100..
DOI: 10.1080/14656566.2020.1853100
Consoli A., Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes Metab. 2013;15(11):967–977. https://doi.org/10.1111/dom.12101..
DOI: 10.1111/dom.12101
Вербовой А.Ф. Метаболический синдром. Самара: Волга-Бизнес; 2010. 48 с.
Wagenknecht L.E., Zaccaro D., Espeland M.A., Karter A.J., O’Leary D.H., Haffner S.M. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol. 2003;23(6):1035–1041. https://doi.org/10.1161/01.ATV.0000072273.67342.6D..
DOI: 10.1161/01.ATV.0000072273.67342.6D
Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H. et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26(9):2493–2499. https://doi.org/10.2337/diacare.26.9.2493..
DOI: 10.2337/diacare.26.9.2493
Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D’Agostino R.B. Sr et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572–2581. https://doi.org/10.1001/jama.296.21.joc60158..
DOI: 10.1001/jama.296.21.joc60158
Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573. https://doi.org/10.1001/jama.299.13.1561..
DOI: 10.1001/jama.299.13.1561
Gast K.B., Tjeerdema N., Stijnen T., Smit J.W., Dekkers O.M. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE. 2012;7(12):e52036. https://doi.org/10.1371/journal.pone.0052036..
DOI: 10.1371/journal.pone.0052036
Wilcox R., Kupfer S., Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008;155(4):712–717. https://doi.org/10.1016/j.ahj.2007.11.029..
DOI: 10.1016/j.ahj.2007.11.029
Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772–1780. https://doi.org/10.1016/j.jacc.2006.12.048..
DOI: 10.1016/j.jacc.2006.12.048
Erdmann E., Charbonnel B., Wilcox R.G., Skene A.M., Massi-Benedetti M., Yates J. et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773–2778. https://doi.org/10.2337/dc07-0717..
DOI: 10.2337/dc07-0717
Viscoli C.M., Brass L.M., Carolei A., Conwit R., Ford G.A., Furie K.L. et al. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J. 2014;168(6):823–829.e6. https://doi.org/10.1016/j.ahj.2014.07.016..
DOI: 10.1016/j.ahj.2014.07.016
Kernan W.N., Viscoli C.M., Furie K.L., Young L.H., Inzucchi S.E., Gorman M. et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321–1331. https://doi.org/10.1056/NEJMoa1506930..
DOI: 10.1056/NEJMoa1506930
Inzucchi S.E., Viscoli C.M., Young L.H., Furie K.L., Gorman M., Lovejoy A.M. et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care. 2016;39(10):1684–1692. https://doi.org/10.2337/dc16-0798..
DOI: 10.2337/dc16-0798
Strongman H., Christopher S., Majak M., Williams R., Bahmanyar S., Linder M. et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. 2018;6(1):e000481. https://doi.org/10.1136/bmjdrc-2017-000481..
DOI: 10.1136/bmjdrc-2017-000481
Tzoulaki I., Molokhia M., Curcin V., Little M.P., Millett C.J., Ng A. et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731. https://doi.org/10.1136/bmj.b4731..
DOI: 10.1136/bmj.b4731
Morgan C.L., Poole C.D., Evans M., Barnett A.H., Jenkins-Jones S., Currie C.J. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(12):4605–4612. https://doi.org/10.1210/jc.2012-3034..
DOI: 10.1210/jc.2012-3034
Morgan C.L., Poole C.D., Evans M., Barnett A.H., Jenkins-Jones S., Currie C.J. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(12):4605–4612. https://doi.org/10.1210/jc.2012-3034..
DOI: 10.1210/ jc.2012-3034
Yang J., Vallarino C., Bron M., Perez A., Liang H., Joseph G., Yu S. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin. 2014;30(11):2223–2231. https://doi.org/10.1185/03007995.2014.941054..
DOI: 10.1185/03007995.2014.941054
Yang J., Vallarino C., Bron M., Perez A., Liang H., Joseph G., Yu S. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin. 2014;30(11):2223–2231. https://doi.org/10.1185/03007995.2014.941054..
DOI: 10.1185/030079 95.2014.941054
Liao H.W., Saver J.L., Wu Y.L., Chen T.H., Lee M., Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927. https://doi.org/10.1136/bmjopen-2016-013927..
DOI: 10.1136/bmjopen-2016-013927
Vaccaro O., Masulli M., Nicolucci A., Bonora E., Del Prato S., Maggioni A.P. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887–897. https://doi.org/10.1016/S2213-8587(17)30317-0..
DOI: 10.1016/S2213-8587(17)30317-0
Zhou Y., Huang Y., Ji X., Wang X., Shen L., Wang Y. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A MetaAnalysis. J Clin Endocrinol Metab. 2020;105(5):dgz252. https://doi.org/10.1210/clinem/dgz252..
DOI: 10.1210/clinem/dgz252
Schernthaner G., Matthews D.R., Charbonnel B., Hanefeld M., Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89(12):6068–6076. https://doi.org/10.1210/jc.2003-030861..
DOI: 10.1210/jc.2003-030861
Schneider C.A., Ferrannini E., Defronzo R., Schernthaner G., Yates J., Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19(1):182–187. https://doi.org/10.1681/ASN.2007060678..
DOI: 10.1681/ASN.2007060678
Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis. 2010;55(5):835–847. https://doi.org/10.1053/j.ajkd.2009.11.013..
DOI: 10.1053/j.ajkd.2009.11.013
Brunelli S.M., Thadhani R., Ikizler T.A., Feldman H.I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int. 2009;75(9):961–968. https://doi.org/10.1038/ki.2009.4..
DOI: 10.1038/ki.2009.4
Салухов В.В., Ильинская Т.А., Минаков А.А. Влияние современной сахароснижающей терапии на массу тела у больных сахарным диабетом 2 типа. Эндокринология: новости, мнения, обучение. 2022;11(1):39–52. https://doi.org/10.33029/2304-9529-2022-11-1-39-52..
DOI: 10.33029/2304-9529-2022-11-1-39-52
Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А. Ожирение – основа метаболического синдрома. Ожирение и метаболизм. 2021;18(2):142–149. https://doi.org/10.14341/omet12707..
DOI: 10.14341/omet12707
Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А. Ожирение – основа метаболического синдрома. Ожирение и метаболизм. 2021;18(2):142–149. https://doi.org/10.14341/omet12707..
DOI: 10.14341/omet12707.2022;16(10):10–21
Smith S.A. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. Biochimie. 2003;85(12):1219–1230. https://doi.org/10.1016/j.biochi.2003.10.010..
DOI: 10.1016/j.biochi.2003.10.010
Doehner W., Erdmann E., Cairns R., Clark A.L., Dormandy J.A., Ferrannini E., Anker S.D. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012;162(1):20–26. https://doi.org/10.1016/j.ijcard.2011.09.039..
DOI: 10.1016/j.ijcard.2011.09.039
Clarke G.D., Solis-Herrera C., Molina-Wilkins M., Martinez S., Merovci A., Cersosimo E. et al. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Diabetes Care. 2017;40(11):1530–1536. https://doi.org/10.2337/dc17-0078..
DOI: 10.2337/dc17-0078
Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S. et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108(23):2941–2948. https://doi.org/10.1161/01.CIR.0000103683.99399.7E..
DOI: 10.1161/01.CIR.0000103683.99399.7E
Betteridge D.J. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med. 2011;28(7):759–771. https://doi.org/10.1111/j.1464-5491.2010.03187.x..
DOI: 10.1111/j.1464-5491.2010.03187.x